Novus Therapeutics Inc. (NVUS)

4.93 -0.02 (-0.404%)

IEX Real-Time Price

August 17, 2018 EST.

NASDAQ Capital Market : Healthcare

Prev Close 4.95

Price Open 4.98

Volume: 4,055

Avg Volume: 17,329

Market Cap: 46.45M

P/E Ratio -

52 Wk Range 3.12-8.61



NVUS Short Interest Statistics


Report Date
Float Share
Short Interest
Short Ratio
Short % to Float

2018-07-31
8.55M
29,318
1.67
0.34%

2018-07-13
8.53M
23,718
0.90
0.28%

2018-06-29
8.53M
17,992
0.49
0.21%

2018-06-15
8.53M
15,197
0.22
0.18%




NVUS Earning Report


Report Date
Fiscal Period
Announce Time
Estimated EPS(#)
Actual EPS
Surprise Dollar

2018-04-04
Q4 2017
N/A
0.00 (0)
0.00
0.00

2018-04-02
Q4 2017
N/A
0.00 (0)
-0.05
0.00

2018-03-28
Q4 2017
N/A
0.00 (0)
0.00
0.00

2018-03-21
Q4 2017
N/A
0.00 (0)
0.00
0.00

News

Novus Therapeutics Reports Second Quarter 2018 Financial Results (2018-08-07 08:30 Business Wire)

Novus Therapeutics, Inc. (NASDAQ: NVUS), a specialty pharmaceutical company focused on developing products for patients with disorders of the ear, nose, and throat (ENT), today announced financial results for the quarter ended June 30, 2018. We continue to make progress on the OP…

 


Statistics

Shares Outstanding: 9.42M

Top 15 Institution Percent: 76.60

Price To Sales: N/A

Price To Book: 2.16

Revenue: N/A

Gross Profit: N/A

Cash: N/A

Debt: N/A

Return On Assets: -35.08

Return On Equity: -38.87

Profit Margin: N/A

Price History

Beta: 0.52

50-day Moving Avg: 6.37

200-day Moving Avg: 4.99

YTD Change: 23.87

5-day Change: -9.71

1-month Change: -29.06

3-month Change: -17.00

6-month Change: 32.17

1-year Change: 31.12

Revenue Per Share: 0.00

Revenue Per Employee: 0.00



Dividend

Dividend Yield: -

EX-Dividend Date: -

Dividend Rate: -


Company Profile

Name: Novus Therapeutics Inc.

Exchange: NASDAQ Capital Market

Industry: Biotechnology

Sector: Healthcare

Website: http://www.novustherapeutics.com

Novus Therapeutics Inc is a pharmaceutical company focusing on the acquisition, development, and commercialization of ear, nose, and throat products. Its technologies have the potential to be developed for multiple ENT indications.